A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
Epistemonikos ID: c048ba071e47983bc13ec67c4bf9835f6efb4d47
First added on: Jul 01, 2025